high risk stage II CC patients after surgery

+

D

Research question: ctDNA analysis is used for the selection of high risk stage II CC patients after surgery. ctDNA positive patients are randomized after surgery for adjuvant chemotherapy or standard of care (no adjuvant treatment)

MEDOCC-CrEATE : Prevention of recurrent disease by additional chemotherapy in patients with detectable circulating
tumor DNA in the blood after surgery for stage II (lymph nodes unaffected) colon cancer.

Research question: ctDNA analysis is used for the selection of high risk stage II CC patients after surgery. ctDNA positive patients are randomized after surgery for adjuvant chemotherapy or standard of care (no adjuvant treatment)

Patients to be included: 1320
Nr. of patients with ctDNA samples: 660
Nr of ctDNA samples: 660
Study design: interventional trial
Tumor type: Colon Caner, stage II
Application of ctDNA: Recurrence risk after surgery

Contact person(s): Prof. M. Koopman (UMCU), Dr G. Vink (UMCU), Dr. Remond Fijneman (NKI-AVL)

Source